Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Med Mycol ; 59(5): 476-485, 2021 May 04.
Artículo en Inglés | MEDLINE | ID: mdl-32823281

RESUMEN

Drug repositioning has been an important ally in the search for new antifungal drugs. Statins are drugs that act to prevent sterol synthesis in both humans and fungi and for this reason they are promissory candidates to be repositioned to treat mycoses. In this study we evaluated the antifungal activity of atorvastatin by in vitro tests to determine the minimum inhibitory concentration against azole resistant Candida albicans and its mechanisms of action. Moreover, the efficacy of both atorvastatin-loaded oral and vaginal emulgels (0.75%, 1.5% and 3% w/w) was evaluated by means of in vivo experimental models of oral and vulvovaginal candidiasis, respectively. The results showed that atorvastatin minimal inhibitory concentration against C. albicans was 31.25 µg/ml. In oral candidiasis experiments, the group treated with oral emulgel containing 3.0% atorvastatin showcased total reduction in fungal load after nine days of treatment. Intravaginal delivery atorvastatin emulgel showed considerable effectiveness at the concentration of 3% (65% of fungal burden reduction) after nine days of treatment. From these findings, it is possible to assert that atorvastatin may be promising for drug repositioning towards the treatment of these opportunistic mycoses.


Atorvastatin is a statin drug that presents antifungal activity. This study showed that atorvastatin-containing oral and vaginal emulgels were able to treat vulvovaginal and oral candidiasis of infected animal model. Therefore, we showcased that atorvastatin may be a possible therapeutic agent in order to be a used to control opportunistic mucosal fungal infections caused by Candida albicans.


Asunto(s)
Atorvastatina/farmacología , Atorvastatina/uso terapéutico , Candida albicans/efectos de los fármacos , Candidiasis Bucal/tratamiento farmacológico , Candidiasis Vulvovaginal/tratamiento farmacológico , Animales , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Azoles/farmacología , Candidiasis Bucal/microbiología , Candidiasis Vulvovaginal/microbiología , Modelos Animales de Enfermedad , Reposicionamiento de Medicamentos , Farmacorresistencia Fúngica , Femenino , Humanos , Ratones , Pruebas de Sensibilidad Microbiana , Ratas , Resultado del Tratamiento
2.
Biomed Pharmacother ; 129: 110432, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32768935

RESUMEN

Gastrointestinal diseases are very common problems; available treatments are very limited and come with a range of side effects. Coumarins are an extensive class of phenolic compounds that can be found in plants, fungi and bacteria. The 7-hydroxycoumarin, also known as umbelliferone (UMB), is a compound that comes from coumarin and has been showing biological activities in other studies. As of this scenario, the present study was designed to evaluate the acute oral toxicity, mutagenic, antidiarrheal, anti-bacterial, and antiulcerogenic effects, and antioxidant capacity of UMB. An investigation was conducted through the hippocratic screening method and through histopathological analysis in animals to evaluate the effects of acute oral administration of a dose of 50, 100 and 200 mg/kg of UMB. A micronucleus test on peripheral blood of Swiss mice, which were orally treated with three doses (50, 100 and 200 mg/kg), was conducted to evaluate mutagenic activities. The antiulcerogenic activity was accomplished through the ethanol-induced damage method. Antidiarrheal activities were tested for inducing diarrhea with castor oil and evaluating intestinal transit duration; additionally, the antimicrobial effect against some enteropathogenic bacteria was analyzed. Finally, the antioxidant capability was determined by the capacity of the UMB sample to kidnap the stable radical 2,2-diphenyl-1-picrylhydrazyl. Of the evaluated doses, signs of toxicity after acute administration of the compound were not observed. UMB presented antiulcerogenic activity (100 and 200 mg/kg), which was explained because of its antioxidant capacity. A gastro protective effect was similar to the positive control, and the UMB was able to significantly reduce intestinal transit, and also diarrheal symptoms. Furthermore, UMB had an anti-bacterial effect with minimum inhibitory concentration fluctuating between 62.5 and 1000 µg/mL. Based on these findings, we can suggest that UMB has important biological activities in vivo and in vitro and is not toxic under the evaluated circumstances, which demonstrates its large potential for pharmacological use.


Asunto(s)
Antiulcerosos/farmacología , Antidiarreicos/farmacología , Diarrea/prevención & control , Úlcera Gástrica/prevención & control , Umbeliferonas/farmacología , Animales , Antibacterianos/farmacología , Antiulcerosos/toxicidad , Antidiarreicos/toxicidad , Bacterias/efectos de los fármacos , Bacterias/crecimiento & desarrollo , Aceite de Ricino , Defecación/efectos de los fármacos , Diarrea/inducido químicamente , Diarrea/fisiopatología , Modelos Animales de Enfermedad , Etanol , Motilidad Gastrointestinal/efectos de los fármacos , Masculino , Ratones , Estómago/efectos de los fármacos , Estómago/patología , Úlcera Gástrica/inducido químicamente , Umbeliferonas/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...